Group 1 - The core objective of the Taizhou Medical High-tech Zone is to establish itself as a leading pharmaceutical city in China and a globally recognized hub, focusing on the full-chain development of the biopharmaceutical industry [1] - The zone implements a targeted talent recruitment system, moving away from a generic approach to focus on key industry needs, ensuring that talent acquisition aligns with industrial development [1][2] - The "113 Medical Talent Special Plan" and "Fengqi High-tech Talent Plan" aim to attract top scientists and industry leaders, while also nurturing managerial talent with experience in listed companies through various incentive mechanisms [1][2] Group 2 - A multi-faceted growth platform is being built to enhance the value of talent, focusing on the entire lifecycle of the biopharmaceutical industry from concept validation to commercialization [2] - The zone emphasizes a "talent first" philosophy, providing comprehensive support through policy, service, and emotional care to create a vibrant environment for talent development [2][3] - The integration of talent, innovation, industry, and capital chains is promoted to create a virtuous cycle that supports the strengthening of the biopharmaceutical industry [3] Group 3 - The complete biopharmaceutical industry chain includes drug research and development, clinical trials, manufacturing, and sales, supported by various innovation platforms and talent teams [3] - Innovative financial service models are being developed to support talent innovation and industry growth, including the establishment of a health industry mother fund to cover the entire lifecycle of enterprises [3]

Economic Development - The "Committee-Director Face-to-Face" event has become a key platform for addressing economic development issues, allowing direct interaction between committee members and department heads [3][4] - The Chengdu Economic and Information Bureau and the New Economy Committee are focusing on precise policy implementation to address development bottlenecks [3] - A committee member highlighted the need for better integration of resources in the biopharmaceutical industry, prompting a commitment from the Economic and Information Bureau to facilitate industry alliances [4] Small and Medium Enterprises - A committee member raised concerns about compliance information access for small and medium enterprises in the new materials sector, suggesting the establishment of a free query platform [5] - The Chengdu Science and Technology Bureau responded positively, indicating plans to create a service platform to assist SMEs with compliance and patent searches [5] Social Welfare and Education - The event also addressed pressing social issues, such as mental health education in schools, with the Education Bureau confirming full coverage of psychological health teachers in all primary and secondary schools [6] - The Chengdu Civil Affairs Bureau is exploring a points-based service system for elderly care, adapting strategies from other cities to meet local aging trends [6] Engagement and Feedback - A total of 265 committee members participated in the event, raising 376 questions, with 372 answered on-site, demonstrating a high level of engagement and responsiveness from government departments [7] - The collaborative atmosphere fostered by the event has been recognized as beneficial for both committee members and government officials, enhancing the quality of policy discussions and implementation strategies [6][7]

Group 1: Core Technology Trends - The global technology wave is reshaping the economic landscape, with a shift from "what can be done" to "what should be done" in 2026, integrating social responsibility into technological development [2] - Artificial intelligence (AI) is the main driver of technological innovation, moving towards large-scale implementation and industrialization [2][3] - AI will transition from conceptual demonstrations to a phase of value realization, focusing on the integration of technology, industry, and governance [3] Group 2: Robotics and AI - Humanoid robots are entering a phase of large-scale trials, driven by breakthroughs in physical AI that allow robots to understand and interact with physical laws [4][5] - The development of humanoid robots will significantly change human-machine coexistence, requiring global collaboration and unified technical standards [5] Group 3: Commercial Space - The commercial space industry in China is poised for significant growth, transitioning from capability building to value creation, with a focus on reusable rockets and satellite networks [6][7] - 2026 is expected to be a pivotal year for the commercialization of space services, driven by advancements in satellite communication technology [7] Group 4: Future Transportation - Super high-speed rail, utilizing low vacuum tube technology, aims to achieve speeds over 1000 km/h, overcoming weather-related disruptions [8][9] - China is at the forefront of this technology, with significant engineering breakthroughs and ongoing trials [10] Group 5: Quantum Technology - Quantum technology is becoming a focal point for global research, with quantum error correction recognized as a key area for future advancements [11][12] - China is positioned in the leading tier of quantum communication and computing, with significant contributions expected from regions like Sichuan [12] Group 6: 6G Technology - The development of 6G technology is underway, promising speeds 10-100 times faster than 5G and enabling comprehensive coverage across air, land, and sea [13][14] - Sichuan is actively working on key technologies to accelerate the industrialization of 6G [15] Group 7: Controlled Nuclear Fusion - Research in controlled nuclear fusion is advancing towards engineering practice, with multiple countries exploring various technological routes [16][17] - China's strategic development in nuclear fusion is gaining momentum, supported by recent legislative frameworks [17] Group 8: Deep Space Exploration - Deep space exploration aims to expand human understanding of the universe, with significant global advancements in observational technology [18][19] - Sichuan is emerging as a key research hub for astronomy and deep space exploration, contributing to national strategic initiatives [19] Group 9: Brain-Computer Interfaces - Brain-computer interfaces are evolving to enhance human-machine interaction, with applications in healthcare and consumer technology [20][21] - Sichuan has developed a complete industry chain for brain-computer interfaces, with a market size of 1 billion yuan, entering a new phase of clinical application [22] Group 10: Biomedicine - The biomedicine sector is a critical area for innovation, integrating biotechnology with pharmaceuticals to drive high-quality development [23][24] - Sichuan is actively cultivating its biomedicine industry, focusing on various key and emerging sectors to enhance its competitive edge [24]

Core Viewpoint - Liaoning Chengda Co., Ltd. plans to establish a biopharmaceutical investment fund in collaboration with its subsidiaries to enhance its competitiveness and capitalize on market opportunities in the healthcare sector [7][11][38]. Group 1: Investment Fund Establishment - The company intends to set up a biopharmaceutical industry investment fund with a total scale not exceeding 1 billion yuan, with an initial scale of 502 million yuan [7][11]. - The fund will focus on the life and health sector, particularly in areas such as innovative drugs, vaccines, and medical services [18][38]. - The fund's structure includes contributions from various subsidiaries, with Liaoning Chengda contributing 100 million yuan, representing approximately 19.92% of the initial fund size [8][11]. Group 2: Investment Strategy and Management - The fund will be managed by Chengda Coastal Industry (Dalian) Fund Management Co., Ltd., which is a wholly-owned subsidiary of the company [14][22]. - The investment strategy includes direct investments in high-quality projects and potential collaborations with other professional investors [18][19]. - The fund aims to achieve returns through strategic investments and timely exits from projects [19][20]. Group 3: Subsidiary Establishment - Liaoning Chengda's subsidiary, Chengda Biological Co., Ltd., plans to establish a wholly-owned subsidiary named Chengda Biological Innovation Pharmaceutical Co., Ltd. with a registered capital of 1 billion yuan [42][44]. - The investment will focus on innovative drug research and development, project acquisitions, and building a professional operational system [44][50]. - This move is part of the company's strategy to diversify its business and enhance its resilience against market fluctuations [50][52].

Core Insights - The A-share biopharmaceutical companies are expected to deliver innovative results in 2025, benefiting from industry recovery, overseas market expansion, and favorable pharmaceutical policies [2] - Over 90 A-share biopharmaceutical companies have released performance forecasts for 2025, with 53 companies expected to be profitable [2] - Among the profit forecasts, 14 companies anticipate a net profit increase of over 100%, while 10 companies expect to turn losses into profits [3][2] Group 1: Performance Growth Drivers - Sales volume growth and internal cost reduction are key factors for the significant profit increases among the companies [4] - Shanghai Yizhong leads with a projected net profit increase of 760.18% to 903.54%, expecting a net profit of 60 million to 70 million yuan in 2025 due to its core product being included in the national medical insurance directory [4] - Yuheng Pharmaceutical anticipates a net profit of 350 million to 420 million yuan, a year-on-year increase of 50.37% to 80.44%, driven by steady sales growth of its products [4] - Nawei Technology expects a net profit of 128 million to 145 million yuan, a year-on-year increase of 54.51% to 75.03%, focusing on market strategies in key sectors [4][5] Group 2: International Market Expansion - International business is a significant growth driver for biopharmaceutical companies [6] - WuXi AppTec, a leading CXO company, forecasts a revenue of 45.456 billion yuan, a year-on-year increase of approximately 15.84%, and a net profit of 19.151 billion yuan, a 102.65% increase [6] - Ganli Pharmaceutical expects a net profit of 1.1 billion to 1.2 billion yuan, a year-on-year increase of 78.96% to 95.23%, attributed to steady growth in domestic and international revenues [6] Group 3: Innovation and Recovery - Several innovative drug companies are entering a recovery phase, with many turning losses into profits or significantly reducing losses [8] - BeiGene expects a full-year operating profit for 2025, with revenue projections between 36.2 billion and 38.1 billion yuan, reflecting an upward adjustment from previous estimates [8] - DiZhe Pharmaceutical anticipates a revenue of 800 million yuan, a year-on-year increase of 122.28%, with a reduced net loss of 770 million yuan [9]

Company Overview - Sanofi Guojian (688336) announced its 2025 annual performance forecast, expecting revenue of approximately 4.2 billion yuan, a year-on-year increase of 251.76%, and a net profit attributable to shareholders of around 2.9 billion yuan, reflecting a growth of 311.35% compared to the previous year [2] - The significant increase in performance is attributed to a major collaboration with Pfizer, which involved a licensing fee payment of approximately 2.89 billion yuan for the 707 project, leading to substantial growth in revenue and net profit [2] Business Development Transactions - In May 2025, Sanofi Guojian, along with its subsidiaries, granted Pfizer exclusive rights for the development, production, and commercialization of the 707 project, a bispecific antibody product targeting both PD-1 and VEGF [5] - According to the agreement, Pfizer will pay a non-refundable and non-deductible upfront fee of $1.25 billion, along with potential milestone payments up to $4.8 billion and royalties based on annual net sales in the licensed area [5] Industry Trends - The record-breaking upfront payment of $1.25 billion for this transaction highlights the strength of Chinese innovative drugs and reflects a reassessment of the value of domestic innovations by international giants [7] - In 2025, China approved 76 innovative drugs, surpassing the 48 approved in 2024, marking a historical high. The total value of licensing transactions for innovative drugs exceeded $130 billion, with over 150 deals, significantly higher than the $51.9 billion and 94 deals in 2024 [7] - The bispecific antibody targeting PD-1/VEGF represents a new class of cancer therapies, potentially becoming a cornerstone for next-generation cancer treatments, with several domestic companies engaging in similar business development transactions [7]

文 ： 华创证券首席经济学家 张瑜（执业证号：S0360518090001） 联系人： 陆银波（15210860866） 袁玲玲（微信 Yuen43） 往期重点内容 1月13日《地方两会的"信息点"》 1月15日《浙江率先开局》 1月26日《北京GDP目标维持在5%左右》 | સ્ત્રેફ્ર | | ફ્તિસ્ટે | 今年目标 | 去年目标 | 去年实际 | | --- | --- | --- | --- | --- | --- | | 调整为区间目标， 下调约0.5个点 | | 广东 | 4.5%-5%,在实际工作 中全力争取更好结果 | 5%左右 | 3.9% | | | | 浙江 | 5%-5.5%，在实际工作 中努力争取更好结果 | 5.5%左右 | 5.5% | | 下调0.5 | | 河南 | 5%左右，在实际工作 中努力争取更好结果 | 5.5%左右 | 5.6% | | 仍为点 | 个点 | 天津 | 4.5%，在实际工作中努 力争取更好结果 | 5%左右 | 4.8% | | 位目标 | 基本不变 | 河北 | 2%以下 | 5%以上 | 5.6% | | | | 北京 | 5%左右 ...

Core Viewpoint - Guangdong aims to double its economic output from 14.58 trillion yuan to approximately 29.16 trillion yuan by 2035, with a focus on high-quality development and sustainable growth during the 14th Five-Year Plan period [3][6]. Economic Goals for 2026 - The expected GDP growth for Guangdong in 2026 is set between 4.5% and 5%, with local public budget revenue projected to grow around 3% [6]. - The average annual GDP growth target for the 14th Five-Year Plan period is approximately 5%, emphasizing quality over speed in economic development [6][7]. Achievements During the 14th Five-Year Plan - Guangdong's GDP increased from 11.37 trillion yuan to 14.58 trillion yuan, and per capita GDP rose from 90,000 yuan to 110,000 yuan [9]. - In 2025, Guangdong's total import and export volume reached 9.5 trillion yuan, contributing 24.1% to the national growth [10]. - The province has seen significant growth in new energy vehicles, advanced electronics, high-end equipment, and biomedicine, enhancing its manufacturing sector [9]. Challenges and Opportunities - Guangdong faces external uncertainties, pressure on foreign trade and investment, and the need for a stable transition to new economic drivers [12][13]. - The region's advantages include its strategic position in the Greater Bay Area, a robust industrial base, and a favorable business environment, which are expected to support sustainable development [13].

Core Viewpoint - Wuhan is advancing the "Five Reforms and Four Goods" urban renewal initiative, focusing on transforming existing urban areas rather than primarily on new city development. The experience and challenges of urban renewal in the Optics Valley, a new district, are explored [3][6]. Group 1: Urban Renewal Drivers - The urban renewal in Optics Valley is driven by three main forces: 1. **Large Enterprises**: Transformation of old factories into modern industrial research and development spaces, integrating historical memory with innovative functions [5]. 2. **Universities**: Development of knowledge cities by dissolving boundaries between campuses and urban areas, creating seamless connections within open knowledge districts [5]. 3. **Ecological Framework**: Establishing a green civilization by linking various districts through ecological corridors, promoting a livable wetland city model [5]. Group 2: Institutional Innovations - To achieve the above drivers, institutional innovations are necessary: 1. **Tax and Financial Mechanisms**: Proposing a shared financial mechanism to reduce high renovation costs for enterprises and optimize industrial space [6]. 2. **Land Use Models**: Exploring mixed-use land models around universities to allow flexible property rights and long-term leasing to startups [6]. 3. **Ecological Investment**: Addressing the high costs of wetland restoration by converting ecological value into development capital through mechanisms like VEP and TDR [6]. Group 3: Future Urban Competitiveness - The future urban competition will focus on functionality and ecology, aiming to provide an ideal habitat for innovative talents and enterprises that integrates living, working, and creating [7]. - The Hubei Provincial Science and Technology Investment Group is working on urban renewal projects to optimize street aesthetics, pedestrian systems, and commercial layouts, creating integrated designs for businesses and talent [7].

Core Viewpoint - The Xuhui District of Shanghai is committed to enhancing its business environment through the "Action Plan for Accelerating the Creation of an International First-Class Business Environment (2026)", which includes 22 tasks and 96 detailed measures aimed at fostering a supportive ecosystem for enterprises and promoting high-quality regional development [1][2]. Group 1: Economic Performance - In 2025, Xuhui District achieved a GDP of 415.308 billion yuan, reflecting a year-on-year growth of 5.5% [2] - The district's fiscal revenue reached 30.925 billion yuan, with a year-on-year increase of 9.71% [2]. Group 2: Investment and Projects - A total of 16 key projects were signed at the conference, covering various sectors such as artificial intelligence, biomedicine, marketing technology, beauty care, and pet economy [2]. - Xuhui District is home to 175 regional headquarters of multinational companies and foreign R&D centers, with foreign enterprises constituting 17% of the total number of companies in the district and contributing nearly 50% of the economic output [2]. Group 3: Corporate Development - The global precision instrument leader, Mettler-Toledo, has established its presence in the Xuhui District, evolving from a startup team to a core enterprise that independently develops and supplies leading products for laboratory and industrial analysis [2]. - Mettler-Toledo plans to increase its investment in Xuhui District, indicating a strong partnership and commitment to the "Industrial Upgrading" strategic cooperation [2].